Home > Quotes > BMRN
BMRN

BioMarin Pharmaceutical Inc. Stock Quote & Summary Data

$57.21
*  
1.10
  negative  
1.89%
Get BMRN Alerts
*Delayed - data as of Jun. 19, 2013 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    BMRN After Hours
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

Best Bid /Ask: $ 57.10 / $ 58.84
1 Year Target: 69.5
Today's High/Low:  / 
Share Volume:
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. 1,534,635
Previous Close: $ 58.31
52 Week High /Low: $ 71.56 / $ 35.99
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. $ 7,952,772,112
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. NE
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -1.05
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 1.27
NASDAQ Official Open Price NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues. $ 58.30
Date of Open Price This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ. Jun. 19, 2013
NASDAQ Official Close Price The NASDAQ® Official Closing Price (NOCP) is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues. The NOCP replaces the NASDAQ market-specific closing price that was based solely on the last reported NASDAQ trade. Subject to review by NASDAQ MarketWatch, the NOCP will equal the normalized price of the last trade reported to NASDAQ’s proprietary trade reporting system—Automated Confirmation Transaction ServiceSM (ACTSM—with a last sale eligible sale condition modifier as of 4:00:02 p.m., US Eastern Time. "Normalizing" the NOCP means it will be adjusted to the nearest prevailing inside quote whenever the last sale is reported away from the inside market. Market participants, data distributors and investors will be provided with the NOCP for all NASDAQ Global Select MarketSM, NASDAQ Global MarketSM and NASDAQ Capital MarketSM securities. $ 57.21
Date of Close Price This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ. Jun. 19, 2013
Community Sentiment

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

ETFs with BMRN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
5.34% First Trust Amex Biotechnology Index Fund (FBT) +7.81  (15.81%)
5.29% PowerShares Dynamic Biotech &Genome (PBE) +1.82  (7.60%)
3.19% iShares NASDAQ Biotechnology Index Fund (IBB) +31.86  (22.02%)
2.85% SPDR Series Trust SPDR S&P Biotech ETF (XBI) +15.12  (17.55%)
2.41% First Trust Health Care AlphaDEX (FXH) +5.24  (14.80%)

We make it easy to follow the leaders. PowerShares QQQ. 100 companies at the top of innovation in one fund.


*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.

**Green highlights the top performing ETF by % change in the past 100 days.

 Company Description (as filed with the SEC)

BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. Our product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Naglazyme received marketing approval in the United States (U.S.) in May 2005, in the European Union (EU) in January 2006 and subsequently in other countries. Kuvan was granted marketing approval in the U.S. and EU in December 2007 and December 2008, respectively.  ... More ...  



News Headlines for BMRN

Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
6/14/2013 8:00:00 AM - PR Newswire
Biomarin Pharma To Present At Goldman Sachs Global Conference; Webcast At 1:00PM
6/13/2013 12:00:00 PM - RTT News
UPDATE: Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Goldman Sachs Global Healthcare Conference
6/6/2013 10:46:00 AM - GlobeNewswire
BioMarin to Present at the Goldman Sachs Global Healthcare Conference
6/6/2013 9:00:00 AM - GlobeNewswire
Biomarin Pharma To Present At Jefferies Global Conference;Webcast At 8:30 AM ET
6/5/2013 7:30:00 AM - RTT News
 

Consensus Recommendation